2026-05-17T05:52:38Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/190162025-04-24T12:48:23Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16968

00925njm 22002777a 4500 dc Maurel, Marine author Pozo Sanchez, Francisco author Pérez-Gimeno, Gloria author Buda, Silke author Sève, Noémie author Oroszi, Beatrix author Hooiveld, Mariëtte author Gomez, Verónica author Domegan, Lisa author Martínez-Baz, Iván author Ilić, Maja author Carnahan, AnnaSara author Mihai, Maria Elena author Martínez, Ana author Goerlitz, Luise author Enouf, Vincent author Horváth, Judit Krisztina author Dijkstra, Frederika author Rodrigues, Ana Paula author Bennett, Charlene author Trobajo-Sanmartín, Camino author Mlinarić, Ivan author Latorre-Margalef, Neus author Ivanciuc, Alina author Lopez, Aurora author Dürrwald, Ralf author Falchi, Alessandra author Túri, Gergő author Meijer, Adam author Melo, Aryse author O'Donnell, Joan author Castilla, Jesús author Vučina, Vesna Višekruna author Hagey, Tove Samuelsson author Lazar, Mihaela author Kaczmarek, Marlena author Bacci, Sabrina author Kissling, Esther author VEBIS study team author 2024-01 Background: Influenza A(H3N2) viruses dominated early in the 2022-2023 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test-negative study. Materials and methods: Primary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, influenza (sub)type and clade, by age group, by influenza vaccine target group and by time since vaccination, using logistic regression. Results: We included 38 058 patients, of which 3786 were influenza A(H3N2), 1548 influenza A(H1N1)pdm09 and 3275 influenza B cases. Against influenza A(H3N2), VE was 36% (95% CI: 25-45) among all ages and ranged between 30% and 52% by age group and target group. VE against influenza A(H3N2) clade 2b was 38% (95% CI: 25-49). Overall, VE against influenza A(H1N1)pdm09 was 46% (95% CI: 35-56) and ranged between 29% and 59% by age group and target group. VE against influenza A(H1N1)pdm09 clade 5a.2a was 56% (95% CI: 46-65) and 79% (95% CI: 64-88) against clade 5a.2a.1. VE against influenza B was 76% (95% CI: 70-81); overall, 84%, 72% and 71% were among 0-14-year-olds, 15-64-year-olds and those in the influenza vaccination target group, respectively. VE against influenza B with a position 197 mutation of the hemagglutinin (HA) gene was 79% (95% CI: 73-85) and 90% (95% CI: 85-94) without this mutation. Conclusion: The 2022-2023 end-of-season results from the VEBIS network at primary care level showed high VE among children and against influenza B, with lower VE against influenza A(H1N1)pdm09 and A(H3N2). Influenza Other Respir Viruses. 2024 Jan 10;18(1):e13243. 10.1111/irv.13243 1750-2659 Influenza and other respiratory viruses 38204584 http://hdl.handle.net/20.500.12105/19016 Europe Influenza Influenza vaccine Multicentre study Vaccine effectiveness Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study